User:Mr. Ibrahem/Oxybutynin

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Oxybutynin
Clinical data
Trade namesDitropan, others
AHFS/Drugs.comMonograph
MedlinePlusa682141
License data
Pregnancy
category
  • AU: B1
Routes of
administration		By mouth, transdermal gel, transdermal patch
Drug classAntimuscarinic[1]
Legal status
Legal status
Pharmacokinetic data
Protein binding91–93%
Elimination half-life12.4–13.2 hours
Identifiers
  • 4-Diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylethanoate
Chemical and physical data
FormulaC22H31NO3
Molar mass357.494 g·mol−1
3D model (JSmol)
  • O=C(OCC#CCN(CC)CC)C(O)(c1ccccc1)C2CCCCC2
  • InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3 checkY
  • Key:XIQVNETUBQGFHX-UHFFFAOYSA-N checkY
  (verify)

Oxybutynin, sold as under the brand names Ditropan among others, is a medication used to treat overactive bladder.[1] It works similar to tolterodine.[1] While used for bed wetting in children, evidence to support this use is poor.[1] It is taken by mouth or applied to the skin.[1]

Common side effects include dry mouth, dizziness, constipation, trouble sleeping, and urinary tract infections.[1] Serious side effects may include urinary retention and an increased risk of heat stroke.[1] Use in pregnancy appears safe but has not been well studied while use in breastfeeding is of unclear safety.[3] It is an antimuscarinic and works by blocking the effects of acetylcholine on smooth muscle.[1]

Oxybutynin was approved for medical use in the United States in 1975.[1] It is available as a generic medication which is inexpensive.[4] A month supply in the United Kingdom costs the NHS less than GB£3 per month as of 2019.[5] In the United States the wholesale cost of this amount is about US$14.[6] In 2017, it was the 100th most commonly prescribed medication in the United States, with more than seven million prescriptions.[7][8]

References[edit]

  1. ^ a b c d e f g h i j k "Oxybutynin Chloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 24 June 2019. Retrieved 3 March 2019.
  2. ^ a b "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 31 October 2020. Retrieved 6 September 2020.
  3. ^ "Oxybutynin Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
  4. ^ Hitchings, Andrew; Lonsdale, Dagan; Burrage, Daniel; Baker, Emma (2019). The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing (2nd ed.). Elsevier. pp. 76–77. ISBN 978-0-7020-7442-4. Archived from the original on 2021-05-22. Retrieved 2021-11-09.
  5. ^ British National Formulary: BNF 76 (76th ed.). Pharmaceutical Press. 2018. ISBN 9780857113382.
  6. ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
  7. ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  8. ^ "Oxybutynin - Drug Usage Statistics". ClinCalc. Archived from the original on 2 July 2020. Retrieved 11 April 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Oxybutynin&oldid=1078351271"